替加环素、米诺环素、多黏菌素B对碳青霉烯类敏感性降低和不敏感鲍曼不动杆菌体外抗菌活性

目的调查替加环素、米诺环素、多黏菌素B等对碳青霉烯类抗生素敏感性降低鲍曼不动杆菌（CDSAB）和碳青霉烯不敏感鲍曼不动杆菌（CNSAB）体外抗菌活性,为临床治疗该类菌感染提供依据。方法采用琼脂稀释法检测替加环素、米诺环素、多黏菌素B等15种抗菌药物对2002-2009年深圳市人民医院临床分离56株CDSAB（美罗培南和亚胺培南MIC=1～4mg／L）和178株CNSAB（美罗培南或亚胺培南MIC≥8mg／L）的最低抑菌浓度（MIC）,采用WHONET5．6软件分析处理数据。结果多黏菌素B对CDSAB和CNSAB体外抗菌活性最高,细菌对其均100％敏感,MIC50和MIC90均为1mg／L,其次为替加环素和米诺环素,约80％CDSAB对二者敏感或中介,MIC50／MIC90分别为4／8mg／L和8／16mg／L;约95％CNSAB对替加环素和米诺环素敏感或中介,MIC50／MIC90分别为4／4mg／L和4／8mg／L。结论多黏菌素B、替加环素和米诺环素对碳青霉烯类抗生素敏感性降低和不敏感鲍曼不动杆菌具有较强的体外抗菌活性。     

114例急性乳腺炎患者乳汁中细菌的检测和耐药性分析

目的 检测急性乳腺炎患者乳汁中细菌的分布和耐药性,为临床合理使用抗菌药物提供重要依据。方法 对114例急性乳腺炎患者的乳汁标本进行细菌培养、鉴定和药物敏感试验。结果 114例标本共分离细菌67株,检出率为58.8%。主要细菌分别为金黄色葡萄球菌[50.7%(34/67)]和表皮葡萄球菌[44.8%(30/67)],其他细菌包括大肠埃希菌[1.49%(1/67)]、肺炎克雷伯菌[1.49%(1/67)]、醋酸不动杆菌[1.49%(1/67)]。耐甲氧西林凝固酶阳性金黄色葡萄球菌(MRSA)与耐甲氧西林凝固酶阴性葡萄球菌(MRCNS)的检出率分别为8.8%与46.7%。3株MRSA对米诺环素、万古霉素、替考拉宁和呋喃妥因的敏感率均为100.0%,31株甲氧西林敏感凝固酶阳性金黄色葡萄球菌(MSSA)对万古霉素、替考拉宁、左氧氟沙星、呋喃妥因、苯唑西林的敏感率均为100.0%,16株甲氧西林敏感凝固酶阴性葡萄球菌(MSCNS)对米诺环素、利福平、呋喃妥因、万古霉素、替考拉宁和苯唑西林的敏感率均为100.0%,14株MRCNS对万古霉素、替考拉宁、米诺环素和呋喃妥因的敏感率均为100.0%。MRSA、MSSA、MSCNS、MRCNS对青霉素的耐药率均为100.0%。结论 急性乳腺炎患者乳汁中细菌主要为葡萄球菌,青霉素不应作为首选治疗的抗菌药物。     

头孢地尼对临床分离菌的体外抗菌活性

目的:测定头孢地尼体外抗菌活性并与其他抗菌药比较。方法:采用琼脂稀释法测定抗生素最低抑菌浓度(MIC)。结果:651株细菌测定结果表明,头孢地尼对甲氧西林敏感金黄色葡萄球菌、表皮葡萄球菌(MSSA、MSSE)抗菌作用与头孢唑林、头孢呋辛相似,较头孢他啶强;对 MSSA、MSSE的 MIC90分别为 1、0.5 mg/L,细菌敏感率分别为 97%、100%。耐甲氧西林金黄色葡萄球菌、表皮葡萄球菌(MRSA、MRSE)、肠球菌对本药耐药,MIC90分别为＞128mg/L、8mg/L、＞128mg/L。头孢地尼对革兰阴性菌抗菌活性与头孢他啶相似,对大肠埃希菌、肺炎克雷伯菌、伤寒杆菌、痢疾杆菌、奇异变形杆菌MIC90分别为 2、4、1、0.25与 2 mg/L,敏感率分别为 85%、88%、100%、100%、88%,对部分细菌抗菌活性较阿米卡星、左氧氟沙星、司帕沙星强。聚团肠杆菌、阴沟肠杆菌、粘质沙雷菌、醋酸钙不动杆菌、铜绿假单胞菌对本药耐药,MIC90均＞128 mg/L。结论:头孢地尼对甲氧西林敏感葡萄球菌属、常见肠杆菌科细菌具强大的抗菌作用。     

国产和进口替加环素体外抗菌活性比较

目的比较替加环素国产和进口制剂对常见临床分离菌的体外抗菌效果。方法标准肉汤稀释法测定国产与进口替加环素制剂对临床分离菌株最低抑菌浓度(MIC)。结果国产和进口替加环素制剂均具有广谱和强大体外抗菌活性。对于肠杆菌科细菌具有良好的体外抗菌作用,MIC90≤2 mg/L,其中对大肠埃希菌MIC90为0.25 mg/L;对碳青霉烯类敏感和耐药鲍曼不动杆菌的MIC90均分别为0.5 mg/L和2 mg/L;对金黄色葡萄球菌、表皮葡萄球菌、肠球菌属MIC90均为0.25 mg/L;对肺炎链球菌MIC90分别为0.25 mg/L和0.125 mg/L;对流感嗜血杆菌和卡他莫拉菌MIC90≤0.125 mg/L;对嗜麦芽窄食单胞菌抗菌活性稍差,MIC90为4 mg/L;2种制剂对各种细菌敏感率几乎相同,对各种细菌的累积抑菌曲线也几乎重叠。结论替加环素具有强大广谱体外抗菌活性,对各种耐药菌抗菌作用突出;进口与国产替加环素制剂体外抗菌效果相同。     

评估国产利奈唑胺对葡萄球菌和肠球菌体外抗菌活性

目的以进口利奈唑胺(原研药)为对照,评估国产利奈唑胺(仿制药)的体外抗菌活性及与进口利奈唑胺的一致性。方法收集6所医院分离的甲氧西林耐药和敏感金黄色葡萄球菌(MRSA、MSSA),甲氧西林耐药和敏感凝固酶阴性葡萄球菌(MRCNS、MSCNS),万古霉素耐药肠球菌(VRE)临床分离菌株,采用CLSI推荐的微量肉汤稀释法进行抗菌药物敏感性试验。结果国产利奈唑胺对金黄色葡萄球菌、凝固酶阴性葡萄球菌及VRE的MIC_(50)和MIC_(90)分别为2 mg/L和4mg/L、1 mg/L和2mg/L及2 mg/L和2mg/L,全部研究菌株对国产利奈唑胺呈现敏感。国产和进口利奈唑胺仅在对MSSA的MIC_(50)上相差一个稀释梯度,两者对其他葡萄球菌和VRE的MIC范围、MIC_(50)和MIC_(90)完全一致。国产和进口利奈唑胺对全部研究菌株抗菌药物敏感性结果的分类一致率(CA)和基本一致率(EA)均高达100%,两者对全部研究菌株的MIC值完全一致或相差不超过±1个稀释梯度。除了MRCNS对替考拉宁的敏感率为88.0%,葡萄球菌对替加环素、达托霉素、万古霉素和替考拉宁的敏感率均高达100%。VRE菌株对替加环素和达托霉素呈现100%敏感率,而对替考拉宁的敏感率仅为50.0%。相比之下,全部菌株对左氧氟沙星的敏感率明显低于其他抗菌药物。结论国产利奈唑胺对多重耐药葡萄球菌及肠球菌具有极好的体外抗菌活性,且与进口利奈唑胺的体外抗菌活性高度一致。     

替加环素对414株需氧革兰阴性和革兰阳性临床分离菌株的体外抗菌活性

目的测定替加环素等15种抗菌药物对我院2004年和2005年临床分离的414株革兰阴性菌和革兰阳性需氧菌的体外抗菌活性。方法采用微量肉汤稀释法测定替加环素等15种抗菌药物对所测菌株的MIC,数据分析采用WHONET5.3软件。结果MRSA对替加环素、利奈唑胺及万古霉素的敏感率均为100%,替加环素对MRSA的MIC90是所测抗菌药物中最低者;万古霉素耐药肠球菌(VRE)对替加环素及利奈唑胺敏感率均为100%,替加环素对所有肠球菌的MIC90分别是利奈唑胺和万古霉素的MIC90的1/8和1/16;替加环素对青霉素中介肺炎链球菌(PISP)的MIC90为0.5mg/L,对青霉素耐药肺炎链球菌(PRSP)的MIC范围是0.25~1mg/L,其他抗菌药物对PISP和PRSP的MIC90是替加环素的1~32倍;替加环素对亚胺培南耐药的鲍曼不动杆菌的MIC范围是其他抗菌药物的1/2~1/64;对铜绿假单胞菌的MIC90是32mg/L;产ESBLs大肠埃希菌和肺炎克雷伯菌对替加环素、美罗培南和亚胺培南敏感率均为100%。结论替加环素对铜绿假单胞菌的抗菌活性较差,对其他需氧革兰阴性杆菌有较好的体外抗菌活性;对需氧革兰阳性球菌的抗菌活性最强。     

替加环素等14种抗菌药物对多重耐药菌的体外抗菌活性研究

目的 评价替加环素等14种抗菌药物对多重耐药细菌的体外抗菌活性.方法 采用微量肉汤稀释法测定替加环素对临床分离的214株多重耐药细菌(MRSA、肠球菌属细菌、鲍曼不动杆菌、产ESBLs大肠埃希菌、产ESBLs肺炎克雷伯菌和肠杆菌属细菌)的MIC,并与其他13种抗菌药物进行比较.数据分析采用WHONET 5.4软件.结果 多重耐药的MRSA对替加环素、万古霉素和利奈唑胺的敏感性均为100%.多重耐药的肠球菌属(粪肠球菌和屎肠球菌)对替加环素和利奈唑胺的敏感率均为100%,万古霉素敏感率为93.1%,2株万古霉素耐药的多重耐药屎肠球菌对替加环素和利奈唑胺均呈敏感,MIC90值分别为0.064 mg/L和1 mg/L.37株多重耐药鲍曼不动杆菌对替加环素的敏感率为97.3%,MIC90值为2 mg/L,其中16株耐美罗培南的鲍曼不动杆菌对替加环素的敏感率仍为100%,MIC90值为2 mg/L.产ESBLs大肠埃希菌和肺炎克雷伯菌对替加环素和美罗培南的敏感率均为100%,但替加环素的MIC90值均高于美罗培南.多重耐药的肠杆菌属细菌(阴沟肠杆菌和产气肠杆菌)对替加环素的敏感率为86.5%,MIC90值为4 mg/L.结论 替加环素对多重耐药的常见需氧革兰阳性球菌和革兰阴性杆菌均有良好的体外抗菌活性.     

米诺环素、替加环素对多重耐药菌的体外抗菌活性比较

目的评价米诺环素、替加环素对多重耐药的耐甲氧西林金葡菌(MRSA)、肠球菌和鲍曼不动杆菌的体外抗菌活性。方法采用微量肉汤稀释法测定临床分离的多重耐药细菌对米诺环素、替加环素的敏感性。结果多重耐药的1 55株鲍曼不动杆菌,99株(63.9%)对米诺环素敏感,39株(25.2%)对米诺环素耐药,17株(11.0%)对米诺环素中介。75株多重耐药MRSA,50株(66.7%)对米诺环素敏感,20株(26.7%)对米诺环素中介,5株(6.7%)为耐药株。93株多重耐药屎肠球菌中36株(38.7%)对米诺环素敏感,57株(61.3%)对米诺环素耐药。39株粪肠球菌中25株(64.1%)对米诺环素敏感。75株MRSA对替加环素100%敏感,132株肠球菌100%敏感。5株耐万古霉素屎肠球菌和4株产新德里金属β内酰胺酶不动杆菌全部对替加环素敏感,MRSA和肠球菌对替加环素敏感性为100%。结论替加环素对米诺环素耐药的肠球菌和MRSA有很好的体外抗菌活性,替加环素对米诺环素耐药的鲍曼不动杆菌的抗菌活性也不理想。     

lycosin-Ⅰ体外抗耐甲氧西林金黄色葡萄球菌活性及联合药敏试验

目的探究lycosin-Ⅰ体外抗耐甲氧西林金黄色葡萄球菌(MRSA)的活性及体外联合8种常用抗菌药物对MRSA的抗菌作用。方法本研究遵循了随机对照试验的设计原则。收集中南大学湘雅二医院2021年9至11月临床分离的MRSA 10株, 采用微量肉汤稀释法测定lycosin-Ⅰ体外抗MRSA的最低抑菌浓度(MIC)、最小杀菌浓度(MBC)和杀菌动力学试验;采用微量肉汤棋盘式稀释法检测lycosin-Ⅰ与青霉素、红霉素、左氧氟沙星、庆大霉素、利福平、米诺环素、万古霉素及利奈唑胺共8种常见抗菌药物的体外联合抑菌效果。结果 lycosin-Ⅰ体外抗MRSA的MIC范围为4～8 mg/L, MIC50和MIC90分别为4和8 mg/L;MBC范围为4～8 mg/L, 其比值MBC/MIC为1～2;杀菌动力学试验结果显示, lycosin-Ⅰ浓度为1/2 MIC或MIC时, MRSA临床分离株和标准菌株均在短时间存活菌数下降而后出现恢复繁殖的现象, 而浓度为2 MIC或4 MIC时存活细菌载量则呈现逐渐减少直至杀灭的趋势。lycosin-Ⅰ与庆大霉素体外联用时以协同作用为主而与其他抗菌药物联用主要表...     

耐甲氧西林金黄色葡萄球菌对3种消毒剂的抗力观察

目的研究耐甲氧西林金黄色葡萄球菌对临床常用化学消毒剂抗力,为实际消毒提供参考。方法采用肉汤稀释法测定3种常用消毒剂对8株临床分离耐甲氧西林金黄色葡萄球菌最小抑菌浓度和最小杀菌浓度,同时与金黄色葡萄球菌标准株作平行比较。结果三氯异氰尿酸对8株临床分离的耐甲氧西林金黄色葡萄球菌的最小抑菌浓度范围为有效氯250～1000mg/L,最小杀菌浓度范围为500～2000mg/L;对金黄色葡萄球菌标准株的MIC为500mg/L,MBC为1000mg/L。碘伏对8株临床分离的耐甲氧西林金黄色葡萄球菌和标准株的MIC和MBC分别为25mg/L和50mg/L。戊二醛对8株临床分离的耐甲氧西林金黄色葡萄球菌和标准株MIC和MBC分别为31mg/L和62mg/L。结论临床分离的耐甲氧西林金黄色葡萄球菌对三氯异氰尿酸的抗力与标准株比较有所不同,但碘伏和戊二醛对耐甲氧西林金黄色葡萄球菌抗力与标准株一致。     

Activity of Tetracycline, Doxycycline, and Minocycline Against Methicillin-Susceptible and -Resistant Staphylococci

Tetracycline, doxycycline, and minocycline were evaluated for their antibacterial activity against methicillin-susceptible and -resistant isolates of Staphylococcus. At clinically achievable levels both doxycycline and minocycline were more active than tetracycline against methicillin-susceptible organisms. Tetracycline and doxycycline had no activity against methicillin-resistant staphylococci, whereas minocycline at 2 mug/ml inhibited six of 13 strains and, at 3 mug/ml, 10 of 13 strains.     

In vitro antibacterial activity of men 10700, a new penem antibiotic

We report here the antibacterial activity of the new penem antibiotic Men 10700 against a total of 740 gram-positive and gram-negative clinical isolates, in comparison to imipenem, meropenem, cefotaxime, ceftriaxone, ciprofloxacin and gentamicin. Men 10700 has shown a wide spectrum of antibacterial activity, with a potent activity both against gram-positive species (with the exception of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis) as indicated by minimal inhibitory concentration (MIC(90)) values < or =0.5 mg/l, and gram-negative species, with MIC(90) values generally < or =2 mg/l. Men 10700 was the most potent antibiotic against methicillin-susceptible S. aureus and S. epidermidis, while the overall spectrum of activity resembled that of imipenem; meropenem was more active against most gram-negative species. In comparison with third-generation cephalosporins, Men 10700 demonstrated superior activity against methicillin-susceptible S. aureus and S. epidermidis and some gram-negative species such as Morganella morganii, Serratia spp. and Enterobacter cloacae; moreover, in contrast to third-generation cephalosporins, Men 10700 showed moderate activity against Enterococcus spp. The activity of Men 10700 against penicillin-resistant Streptococcus pneumoniae (10 strains) and some gram-negative strains selected for their resistance to cefotaxime (20 strains) was particularly interesting. Copyright Copyright 1999 S. Karger AG, Basel.     

Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates

The in vitro activity of moxifloxacin was compared with that of 15 antibacterial agents against 513 Gram-positive microorganisms. The MIC(90) (mg/L) of moxifloxacin was 0.06 for quinolone-susceptible Staphylococcus aureus and Staphylococcus epidermidis, 0.12 for Streptococcus pyogenes and Streptococcus agalactiae; 0.25 for Streptococcus pneumoniae, Streptococcus mitis, Streptococcus bovis, Streptococcus anginosus and Actinomyces pyogenes; 0.5 for Streptococcus sanguis and Listeria monocytogenes, 2 for Corynebacterium jekeium and Bifidobacterium bivius. Over 50% of Enterococcus faecalis, Enterococcus faecium, quinolone-resistant staphylococci, Nocardia steroides and Clostridium difficile were susceptible to 2 mg/L moxifloxacin. Moxifloxacin and trovafloxacin demonstrated comparably high activity towards Gram-positive cocci; moxifloxacin and clinafloxacin were most active against Gram-positive bacilli.     

国产去甲万古霉素对224株肠球菌的体外抗菌活性观察

目的为了观察国产去甲万古霉素对肠球菌的体外抗菌活性。方法用二倍琼脂稀释法测定了224株肠球菌(粪肠球菌169株、屎肠球菌51株和其他肠球菌4株)的最低抑菌浓度,并与进口万古霉素进行了抑菌效果对比。结果国产去甲万古霉素对肠球菌抑菌效果较好,其对224株肠球菌的MIC50和MIC90分别为0.5 mg/L和1mg/L,对169株粪肠球菌和51株屎肠球菌的MIC90分别为1 mg/L和1 mg/L;进口万古霉素对169株粪肠球菌的MIC90为2 mg/L。结论两者抗菌效果均菌较好。对224株肠球菌的敏感率均为100%。     

The in-vitro activity of doxycycline and minocycline against anaerobic bacteria

The likelihood of bacterial resistance now prevents the use of oxytetracycline in the empirical therapy of anaerobic infections. This study investigates the in-vitro activity of two semi-synthetic derivatives, doxycycline and minocycline, against a range of anaerobic bacteria. MICs for each antibiotic were determined by an agar incorporation technique. Doxycycline and minocycline were four to eight times more active against the majority of strains than oxytetracycline. With the exception of Bacteroides bivius, almost 90% of strains were inhibited by 4 mg/l of doxycycline or minocycline, but resistance to the same concentration of oxytetracycline was present in 60% of the B. fragilis group, 30% of Peptostreptococcus spp. and 24% of Clostridium perfringens. Doxycycline and minocycline represent an alternative therapy for anaerobic infections where bacterial sensitivities are known.     

Effect of 5-fluorouracil, mitoxantrone, methotrexate, and vincristine on the antibacterial activity of ceftriaxone, ceftazidime, cefotiam, piperacillin, and netilmicin

Using the checkerboard agar dilution technique, antibacterial activity and in vitro interactions of 4 antineoplastic agents and 5 antimicrobial drugs were examined against 56 strains of 7 bacterial species. 5-fluorouracil was found to inhibit all strains of Staphylococcus aureus and of Staphylococcus epidermidis at a concentration of 0.8 micrograms/ml or less. 84% of all gram-negative strains were inhibited synergistically when 5-fluorouracil was combined with beta-lactam antibiotics. Methotrexate and cefotiam were antagonistic in 42% of all combinations, especially when tested against Escherichia coli and Klebsiella pneumoniae.     

Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.

We studied the comparative in vitro activity of ertapenem, a new carbapenem, against 240 aerobic and 180 anaerobic recent clinical bite isolates using an agar dilution method and an inoculum of 10(4) cfu/spot for aerobes and 10(5) cfu/spot for anaerobes. Ertapenem inhibited 410/420 (98%) of the isolates tested at < or = 4 mg/L with only 4/5 Campylobacter gracilis and 1/3 Campylobacter rectus strains requiring . or = 16 mg/L for inhibition. Ertapenem was only moderately active (MIC 8 mg/L) against 4/6 Enterococcus faecalis and 1/11 Staphylococcus epidermidis strains. All Pasteurella multocida, Pasteurella septica, Pasteurella canis, Pasteurella dagmatis, Moraxella spp. and EF-4 isolates were inhibited at < or = 0.015 mg/L. MIC(90)s for other aerobic genera and species were as follows: Corynebacterium spp., 4 mg/L; Staphylococcus aureus, 0.25 mg/L; Staphylococcus epidermidis, 4 mg/L; other coagulasenegative staphylococci, 0.25 mg/L; Streptococcus milleri group, 0.5 mg/L; Eikenella corrodens, 0.03 mg/L; and Bergeyella zoohelcum, 0.5 mg/L. For anaerobes the range of MICs and MIC(90)s were: Prevotella ssp., < or = 0.015-0.5, 0.125 mg/L; Porphyromonas spp., < or = 0.015-0.03, 0.015 mg/L; Fusobacterium spp., 0.015-0.125, 0.03 mg/L; Bacteroides tectum, 0.03-0.125, 0.125 mg/L; and Peptostreptococcus spp., 0.01-2, 1 mg/L. Ertapenem showed excellent potency against the full range of animal and human bite wound pathogens.     

In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone.

The in vitro and in vivo antibacterial activities of KB-5246, a tetracyclic quinolone, were compared with those of ciprofloxacin, ofloxacin, and norfloxacin. KB-5246 demonstrated a broad antibacterial spectrum. The in vitro activity of KB-5246 against gram-negative bacteria was higher than that of ofloxacin or norfloxacin and was comparable to that of ciprofloxacin. KB-5246 demonstrated the greatest activity against gram-positive bacteria of the four agents tested. Among Streptococcus pyogenes strains resistant to 1.56 micrograms of norfloxacin per ml, there were 26 strains susceptible to 0.2 micrograms of KB-5246 per ml. Similarly, among the Staphylococcus aureus and Staphylococcus epidermidis strains resistant to 3.13 micrograms of norfloxacin per ml, there were 23 S. aureus and 11 S. epidermidis strains susceptible to 0.39 micrograms of KB-5246 per ml. Among the Streptococcus pneumoniae and Enterococcus faecalis strains resistant to 12.5 micrograms of norfloxacin per ml, there were 5 S. pneumoniae and 10 E. faecalis strains susceptible to 0.39 micrograms of KB-5246 per ml. KB-5246 had bactericidal activity at the MIC. KB-5246 demonstrated excellent antibacterial activity against various systemic infections in mice. After oral administration, KB-5246 was as active as ofloxacin and about two times more active than norfloxacin.     

Antibiotics and prevention of microbial colonization of catheters.

Slime-producing staphylococci frequently colonize catheters, and when they are embedded in biofilm, they become resistant to various antibiotics. In the study that is described, the comparative efficacies of vancomycin, clindamycin, novobiocin, and minocycline, alone or in combination with rifampin, were tested in an in vitro model of colonization. The model consisted of the modified Robbins device with antibiotic-impregnated cement filling the lumen of catheter segments. The synergistic combination of minocycline and rifampin was the most efficacious in preventing bacterial colonization of slime-producing strains of Staphylococcus epidermidis and Staphylococcus aureus to catheter surfaces. A similar trend was observed when the inhibitory activities of polyurethane catheters coated with minocycline and rifampin were compared with the inhibitory activities of catheters coated with other antimicrobial agents. The inhibitory activities of catheters coated with minocycline and rifampin against S. epidermidis, S. aureus, and Enterococcus faecalis strains, for example, were significantly better than those of catheters coated with vancomycin (P < 0.05). The inhibitory activities of catheters coated with minocycline and rifampin against gram-negative bacilli and Candida albicans were comparable to those of catheters coated with ceftazidime and amphotericin B, respectively. We found that the combination of minocycline and rifampin is unique and highly effective in preventing the colonization of catheters with slime-producing staphylococci and that it also displays a broad-spectrum inhibitory activity against gram-negative bacteria and yeast cells.